$6.31
Today
as of Jul 22, 16:45 ET
Last 30 days
Recent Press Releases & News
Achieve Life Sciences Stockholders Weigh Board Slate, Share Increase at Annual Meeting
Achieve Life Sciences Joins Russell 2000® Index
Achieve Life Sciences Receives FDA Complete Response Letter for Cytisinicline
Overview
52-week range
$2.00
$6.15
100% of range
Avg surprise (last 3)
+12.2%
Avg reaction (last 2)
+7.0%
100% positive
Latest IV / EM
113%
EM ±25.8% · $8 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $-0.19 | $-0.30 | +36.7% | +48.6% | +7.2% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.28 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.37 | $-0.37 | 0.0% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.37 | $-0.37 | 0.0% | — | +6.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.36 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.25 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.26 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.34 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.43 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.18 | -$0.37 | +51.4% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | $-10M | — | $-14M | $-13M | $-13M | — | $-13M | $-8M |
| EPS (diluted) | $-0.19 | — | $-0.28 | $-0.37 | $-0.37 | — | $-0.36 | $-0.25 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $28M | $21M | $32M | $52M | $13M | $13M | $10M | $15M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $31M | $40M | $50M | $57M | $25M | $36M | $46M | $63M |
| Total assets | $33M | $42M | $52M | $59M | $27M | $39M | $48M | $65M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $22M | $20M | $18M | $17M | $17M | $18M | $17M | $23M |
| Total equity | $11M | $22M | $34M | $42M | $10M | $21M | $31M | $42M |